Evaluating thresholds of Mac-2 binding protein glycosylation isomer in association with clinical outcomes in patients with cirrhosis

Table 2 Serum mac-2 binding protein glycosylation isomer according to the degree of cirrhosis, esophageal varices, and with or without hepatocellular carcinoma, mean ± SD

Characteristic	n	M2BPGi C.O.I.	P value1
Child-Pugh
A	22	5.20 ± 2.65	< 0.001
B	64	6.14 ± 2.89
C	67	8.63 ± 4.08
MELD score
≤ 9	38	6.09	0.003
10-19	53	6.43
20-29	39	7.85
30–39	10	10.02
≥ 40	7	11.11
Esophageal varices
F0	22	5.3 ± 4.3	< 0.05
F1	10	5.0 ± 3.8
FII	21	7.6 ± 3.4
FIII	57	8.1 ± 3.8
HCC
Yes	28	8.8 ± 2.9	< 0.05
No	125	6.7 ± 3.8

¹Analysis of variance was performed to evaluate the difference amongst the group; P < 0.05 was considered statistically significant.

HCC: Hepatocellular carcinoma; C.O.I.: Cutoff index; M2BPGi: Mac-2 binding protein glycosylation isomer; MELD: Model for end-stage liver disease.